
News
Home>News & Events>Publications>CDRC>The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions
Related Posts
-
C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform
-
C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals
-
Webinar: TRxA 2023 Funding Opportunities
-
Using Real World Data from CURE ID to Identify Drug Repurposing Opportunities in Mycology: Impact of Climate Change
-
Polycystic Kidney Disease Drug Development: A Conference Report